• Full Year FY2025 Revenue guidance upgraded from $25m to $28m
• Revenue for H1 FY2025 was $12.6m, a 267% increase
• Revenue for H2 FY2025 expected to be $15.4m, a 226% increase

Bioxyne Limited (ASX: BXN) has upgraded its full year FY2025 revenue guidance from $25 million to $28 million. The key highlights are: Revenue for H1 FY2025 was $12.6 million, representing a 267% increase on the previous half, and revenue for H2 FY2025 is expected to be $15.4 million, a 226% increase on the prior corresponding period (H2 FY2024). Australian pharmaceutical manufacturing and supply has been a key driver of growth in FY25, and the Company expects continued growth in its Australian operations in FY2026. The Company is also making significant progress in Germany and the UK and will provide a market update shortly. Bioxyne's wholly owned subsidiary Breathe Life Sciences (BLS) is the Australian market leader in the manufacture of medicinal cannabis, MDMA, and Psilocybin products, contributing to Bioxyne's growth in FY2025. Bioxyne operates in Medical Cannabis markets with estimated annualized revenues of over $3 billion in 2025, and the global psychedelic drugs market is projected to grow to $14 billion by 2032. Bioxyne is positioning for long term success in its psychedelic business, with its MDMA capsules, BLSMD40 and BLSMD100, going into commercial batch production in July.

Bioxyne has upgraded its full year FY2025 revenue guidance from $25 million to $28 million.

Bioxyne is positioned for continued growth in FY2026, attributable to further expansion of its business in Australia as well as entry into new high-growth opportunity markets including the UK, Germany and other EU countries.